Use the hyperlinks, where available to access additional clinical trial information.
A Phase I/II, First-in-Human, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of a Trispecific EGFR/cMET/cMET Antibody GB263T in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Genor Biopharma Co., Ltd.
This study consists of a dose-escalation and expansion stage (Phase 1) to determine the recommended Phase 2 dose (RP2D), and an extension stage (Phase 2) where participants will be enrolled into specific cohorts based on their diagnosis. Participants will receive GB263T via intravenous infusion (IV) at increasing dose levels until the maximum tolerated dose is reached, or all planned doses are administered. Participants will receive GB263T at predefined dose levels and frequency, based on observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days.